Our Stories
Latest News
Innovation
Caring & Giving
Personal Stories
Health & Wellness
Our Heritage
Our Company
About J&J
Our Credo
Our Leadership Team
Corporate Governance
Diversity & Inclusion
Empowering Women
Innovation at J&J
Office of the Chief Medical Officer
J&J Health and Wellness Solutions
Policies & Statements
Code of Business Conduct
Corporate Reports
Products
Consumer Products
Medical Devices
Pharmaceutical Products
Procurement
Value Pillars
Supplier Diversity
Supplier Standards
Careers
What We Do
How We Hire
Job Spotlight
Employee Benefits
Students
Innovation
Career Stories
Media Center
Investors
Corporate Governance
Quarterly Results
SEC Filings
News Releases
Pharmaceutical Pipeline
2016 Health for Humanity Report
Stock Information
Webcasts & Presentations
Our Societal Impact
Global Community Impact
Global Public Health
Global Environmental Health
Citizenship & Sustainability Reporting
Follow Us
Facebook
Twitter
YouTube
LinkedIn
Explore more Johnson & Johnson sites:
Australia
Argentina
Brazil
Canada
Chile
China
Colombia
Costa Rica
Ecuador
Germany
India
Italy
Japan
Mexico
New Zealand / Pacific
Paraguay
Peru
Philippines
Russia
Switzerland
German
English
French
Italian
Uruguay
United States
Venezuela
Press Release Archive
+
View Filters
All Topics
Caring & Giving
Health & Wellness
Innovation
Our Company
Our Heritage
Our Products
All Dates
Last 30 Days
Last 90 Days
Last Year
Sort by Newest
Sort by Oldest
Innovation
January 23, 2017
The ECHELON FLEX™ GST System Will Now Feature A 45mm Endocutter With Exclusive Gripping Surface Technology Reloads
Ethicon announces 510(k) clearance of the ECHELON FLEX™ GST SYSTEM (45mm)
Innovation
January 20, 2017
Ethicon Announces Acquisition of Megadyne Medical Products, Inc.
Complements and expands Ethicon's advanced energy portfolio with broad range of innovative electrosurgical tools
Innovation
January 19, 2017
IMBRUVICA® (ibrutinib) Approved by FDA for Marginal Zone Lymphoma (MZL) Patients Who Require Systemic Therapy and Have Received At Least One Prior Anti-CD20-Based Therapy
First therapy specifically indicated for this rare blood cancer; represents fifth indication for IMBRUVICA in the U.S.
Innovation
January 10, 2017
Johnson & Johnson Innovation, New York State and New York Genome Center Collaborate to Launch JLABS in New York City
Innovation
January 10, 2017
Dr. Paul Janssen Award for Biomedical Research Issues 2017 Call for Nominations
Our Company
January 09, 2017
Joaquin Duato Named PhRMA Board Chairman
Innovation
January 09, 2017
Johnson & Johnson Medical Devices Companies Launch CareAdvantage, a Suite of Holistic, Insights-Driven Capabilities to Help U.S. Health Systems Navigate Value-Based Care
Innovation
January 09, 2017
Johnson & Johnson Medical Devices Companies Introduce Orthopaedic Episode of Care Approach, Leveraging CareAdvantage Capabilities to Support Better Clinical Outcomes and Reduce the Cost of Care
Innovation
January 05, 2017
Janssen Enters Immunotherapy Clinical Collaboration with Bristol-Myers Squibb to Evaluate daratumumab (DARZALEX®) in Combination with nivolumab (OPDIVO®)
Phase 1b/Phase 2 studies planned in multiple myeloma and solid tumors
Innovation
January 03, 2017
DePuy Synthes Acquires Interventional Spine Expandable Cage Technology to Accelerate Growth in Spine
DePuy Synthes Acquires Interventional Spine Expandable Cage Technology to Accelerate Growth in Spine
See More Press Releases